Kaysen George A, Johansen Kirsten L, Chertow Glenn M, Dalrymple Lorien S, Kornak John, Grimes Barbara, Dwyer Tjien, Chassy Alexander W, Fiehn Oliver
Department of Medicine, University of California, Davis, Davis, California; Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis California.
San Francisco Department of Veterans Affairs Medical Center, San Francisco, California; Department of Medicine, University of California, San Francisco, San Francisco, California.
J Ren Nutr. 2015 Jul;25(4):351-6. doi: 10.1053/j.jrn.2015.02.006. Epub 2015 Mar 19.
Trimethylamine N-oxide (TMAO) is a product of metabolism of phosphatidylcholine (lecithin) and carnitine by the intestinal microbiome. Elevated serum concentrations of TMAO have been linked to adverse cardiovascular outcomes in the general population. We examined correlates of serum TMAO and the relations among serum TMAO concentrations, all-cause mortality, and cardiovascular mortality and hospitalizations in a nationally derived cohort of patients new to hemodialysis (HD).
We quantified serum TMAO by liquid chromatography and online tandem mass spectrometry and assessed nutritional and cardiovascular risk factors in 235 patients receiving HD and measured TMAO in pooled serum from healthy controls. We analyzed time to death and time to cardiovascular death or hospitalization using Cox proportional hazards regression.
Serum TMAO concentrations of patients undergoing HD (median, 43 μM/L; 25th-75th percentile, 28-67 μM/L) were elevated compared with those with normal or near-normal kidney function (1.41 ± 0.49 μM/L). TMAO was directly correlated with serum albumin (Spearman rank correlation, 0.24; 95% CI, 0.12-0.35; P <.001), prealbumin (Spearman rank correlation, 0.19; 95% CI, 0.07-0.31; P = .003), and creatinine (Spearman rank correlation, 0.21; 95% CI, 0.08-0.33; P = .002) and inversely correlated with log C-reactive protein (Spearman rank correlation, -0.18; 95% CI, -0.30 to -0.06; P = .005). Higher serum concentrations of TMAO were not significantly associated with time to death (Spearman rank correlation, 0.84; CI, 0.65-1.09; P = .19) or time to cardiovascular hospitalization or cardiovascular death (Spearman rank correlation, 0.88; CI, 0.57-1.35; P = .55).
Serum TMAO concentrations were markedly elevated and correlated directly with biochemical markers of nutritional status and inversely with markers of inflammation in patients receiving HD. There was no significant association between serum TMAO concentrations and all-cause mortality, cardiovascular death, or hospitalizations. In patients receiving dialysis-in contrast with the general population-adverse vascular effects of TMAO may be counterbalanced by associations with nutritional or inflammatory status.
氧化三甲胺(TMAO)是肠道微生物群对磷脂酰胆碱(卵磷脂)和肉碱进行代谢的产物。在普通人群中,血清TMAO浓度升高与不良心血管结局相关。我们在一个全国性的首次接受血液透析(HD)的患者队列中,研究了血清TMAO的相关因素以及血清TMAO浓度、全因死亡率、心血管死亡率和住院率之间的关系。
我们采用液相色谱和在线串联质谱法定量血清TMAO,并评估了235例接受HD治疗的患者的营养和心血管危险因素,同时测定了健康对照者混合血清中的TMAO。我们使用Cox比例风险回归分析死亡时间以及心血管死亡或住院时间。
与肾功能正常或接近正常的患者(1.41±0.49μM/L)相比,接受HD治疗的患者血清TMAO浓度升高(中位数为43μM/L;第25-75百分位数为28-67μM/L)。TMAO与血清白蛋白直接相关(Spearman等级相关系数为0.24;95%CI为0.12-0.35;P<.001)、与前白蛋白直接相关(Spearman等级相关系数为0.19;95%CI为0.07-0.31;P=.003)、与肌酐直接相关(Spearman等级相关系数为0.21;95%CI为0.08-0.33;P=.002),与log C反应蛋白呈负相关(Spearman等级相关系数为-0.18;95%CI为-0.30至-0.06;P=.005)。较高的血清TMAO浓度与死亡时间(Spearman等级相关系数为0.84;CI为0.65-1.09;P=.19)或心血管住院或心血管死亡时间(Spearman等级相关系数为0.88;CI为0.57-1.35;P=.55)无显著相关性。
接受HD治疗的患者血清TMAO浓度显著升高,与营养状况的生化标志物直接相关,与炎症标志物呈负相关。血清TMAO浓度与全因死亡率、心血管死亡率或住院率之间无显著相关性。在接受透析的患者中,与普通人群不同,TMAO的不良血管效应可能被其与营养或炎症状态的关联所抵消。